• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Naphthyridine carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Naphthyridines Naphthyridine carboxylic acids and derivatives

Introduction to 6-Bromo-1,8-naphthyridine-3-carboxylic acid (CAS No. 1105191-97-6)

6-Bromo-1,8-naphthyridine-3-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1105191-97-6, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the naphthyridine class, a structural motif characterized by a fused bicyclic system containing nitrogen atoms. The presence of a bromine substituent at the 6-position and a carboxylic acid functional group at the 3-position imparts unique reactivity and potential biological activity, making it a valuable scaffold for drug discovery and development.

The structural framework of 6-Bromo-1,8-naphthyridine-3-carboxylic acid consists of two fused pyridine rings, with the bromine atom serving as a key handle for further chemical modifications. The carboxylic acid moiety provides an acidic character, enabling various conjugation strategies with other pharmacophores. This combination of features has positioned 6-Bromo-1,8-naphthyridine-3-carboxylic acid as a versatile intermediate in synthetic chemistry, particularly in the design of novel therapeutic agents.

In recent years, there has been growing interest in naphthyridine derivatives due to their demonstrated efficacy in targeting a range of biological processes. The brominated naphthyridines, including 6-Bromo-1,8-naphthyridine-3-carboxylic acid, have been explored for their potential as kinase inhibitors, antimicrobial agents, and anti-cancer compounds. The bromine atom at the 6-position allows for selective cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings, facilitating the introduction of diverse substituents and enhancing the molecular diversity of libraries screened in drug discovery campaigns.

One of the most compelling aspects of 6-Bromo-1,8-naphthyridine-3-carboxylic acid is its utility in medicinal chemistry as a building block for more complex molecules. Researchers have leveraged its scaffold to develop inhibitors targeting enzymes involved in cancer metabolism and signal transduction pathways. For instance, studies have shown that derivatives of this compound can modulate the activity of Janus kinases (JAKs) and tyrosine kinases (Tyrosine Kinase Inhibitors - TKIs), which are critical in regulating immune responses and cell growth. The carboxylic acid group at the 3-position has been particularly useful for forming amide or ester linkages with other pharmacophores, thereby enhancing binding affinity and selectivity.

The synthesis of 6-Bromo-1,8-naphthyridine-3-carboxylic acid typically involves multi-step organic transformations starting from commercially available precursors. A common synthetic route includes the bromination of an appropriate naphthyridine precursor followed by carboxylation at the 3-position. Advances in catalytic methods have enabled more efficient and scalable preparations of this compound, making it more accessible for industrial applications. The purity and yield of synthetic batches are crucial for downstream applications, particularly in pharmaceutical research where impurities can significantly impact biological activity.

The pharmacological profile of 6-Bromo-1,8-naphthyridine-3-carboxylic acid has been investigated through both computational modeling and experimental screening. Computational studies have predicted potential binding modes within target proteins, providing insights into how structural modifications might enhance potency or selectivity. Experimental validation through high-throughput screening (HTS) has identified several derivatives with promising biological activity against cancer cell lines and inflammatory pathways. These findings underscore the importance of 6-Bromo-1,8-naphthyridine-3-carboxylic acid as a lead compound in drug discovery efforts.

Recent advances in biocatalysis have also opened new avenues for utilizing 6-Bromo-1,8-naphthyridine-3-carboxylic acid as a substrate for enzyme-mediated reactions. For example, transaminases have been employed to introduce chiral centers into naphthyridine derivatives with high enantioselectivity. This approach has enabled the rapid generation of enantiopure compounds that exhibit enhanced pharmacological properties compared to their racemic counterparts. Such innovations highlight the growing intersection between synthetic chemistry and enzymatic biocatalysis in optimizing drug candidates.

The role of 6-Bromo-1,8-naphthyridine-3-carboxylic acid extends beyond small-molecule drug development into materials science applications. Its rigid bicyclic structure makes it a suitable candidate for designing organic semiconductors and light-emitting diodes (OLEDs). Researchers have explored its incorporation into π-conjugated systems to improve charge transport properties in electronic devices. These applications demonstrate the broad utility of naphthyridine derivatives beyond traditional pharmaceuticals.

In conclusion,6-Bromo-1,8-naphthyridine-3-carboxylic acid (CAS No. 1105191-97-6) is a multifaceted compound with significant potential across multiple domains of chemical research. Its unique structural features make it an invaluable scaffold for developing novel therapeutics targeting various diseases. As synthetic methodologies continue to evolve and computational tools become more sophisticated,6-Bromo-1,8-naphthyridine-3-carboxylic acid will undoubtedly remain at the forefront of medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)